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Background: The effect of diabetes on survival after resection pancreatic ductal carcinoma (PDAC) is
unclear. The present study was undertaken to determine whether pre-operative diabetes has any
predictive value for survival.
Methods: A retrospective review from seven centres was performed. Metabolic factors, tumour char-
acteristics and outcomes of patients undergoing resection for PDAC were collected. Univariate and
multivariable analyses were performed to determine factors associated with disease-free (DFS) and
overall survival (OS).
Results: Of the 509 patients in the present study, 31.2% had diabetes. Scoring systems were devised
to predict OS and DFS based on a training set (n = 245) and were subsequently tested on an independent
set (n = 264). Pre-operative diabetes (P < 0.001), tumour size >2 cm (P = 0.001), metastatic nodal ratio
>0.1 (P < 0.001) and R1 margin (P < 0.001) all correlated with DFS and OS on univariate analysis. Scoring
systems were devised based on multivariable analysis of the above factors. Diabetes and the metastatic
nodal ratio were the most important factors in each system, earning two points for OS and four points for
DFS. These scoring systems significantly correlated with both DFS (P < 0.001) and OS (P < 0.001).
Conclusion: Pre-operative diabetes status provides useful information that can help to stratify patients
in terms of predicted post-operative OS and DFS.
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Introduction
Pancreatic adenocarcinoma (PDAC) is a devastating disease that
poses significant management challenges. The incidence of PDAC
continues to rise, with over 40 000 newly diagnosed patients and
almost as many patient deaths in 2010. It remains the 10th most
common cancer diagnosis and the 4th leading cause of cancer
death in the USA.1 Although some recent studies have reported
5-year survival rates above 20%,2–4 the overall 5-year survival rate
has changed little over the past 30 years. Although many patients
present with unresectable disease, resection remains the only
chance at long-term survival.
Survival after resection appears to be influenced by several
independent prognostic variables including pre-operative
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comorbidities, clinicopathological characteristics, tumour biology
and peri-operative complications.5–9 Although data are conflict-
ing, patient characteristics such as pre-existing diabetes mellitus
(DM) and obesity have been shown to be associated with long-
term survival after surgical resection.10–13 Others have shown an
increased risk of peri-operative complications with DM and
obesity, but not survival.14–19
Recently, pre-existing DM has been identified as an adverse
prognostic variable associated with increased mortality in various
cancers, including colorectal, prostate and breast cancers.20,21
There is a 40–65% prevalence of coexisting DM in patients
with PDAC and up to 80% with some degree of impaired glu-
cose metabolism,22 illustrating a well-documented relationship
between DM and PDAC.23–27 Less is known, however, about the
impact of pre-operative DM on post-resection outcomes, includ-
ing survival. Chu et al.10 in a retrospective review of 209 patients,
found that pre-existing DM was independently associated with
reduced survival in patients undergoing resection for PDAC. This
was most pronounced in patients with new-onset DM (24
months), in which a larger tumour size was also noted. These
findings suggest that pre-existing DMmay have prognostic impli-
cations after resection for PDAC. This observation was earlier
reported in a retrospective study by Sperti et al.,12 in which DM
was found to be independently associated with long-term survival
in 113 patients who underwent resection for PDAC. Conflicting
data exist,28–30 thus, the true impact of diabetes on pancreatic
cancer outcomes is not fully known.
Complete resection of all disease (R0 resection) is a core prin-
ciple of surgical oncology. Numerous studies in the literature have
shown that a positive resection margin (R1) in surgically treated
PDAC is independently associated with poor long-term survival,
and conversely, a negative margin resection has a positive impact
on survival.31–33 Some previous authors have suggested that a posi-
tive resection margin might represent a more biologically aggres-
sive tumour and thus has significant prognostic implications on
recurrence and survival.34 Although the impact of margin status
has been challenged,35–37 most agree that efforts to obtain a nega-
tive margin probably provide benefit to the patient with PDAC.
Similarly, lymph node status is important as a marker of tumour
biology. The presence of nodal involvement is associated with a
poor prognosis.5,38,39 Lymph node ratio (LNR), rather than overall
nodal status, has been shown to be an important prognostic factor
in gastric and colon cancer.40,41 More recently, several studies have
demonstrated LNR as a valuable marker of survival after resection
for PDAC.42–46 Based on these data, it was hypothesized that sur-
vival models could be created based on pre-existing diabetes mel-
litus, tumour biology and resection status for patients with PDAC.
Methods
Data from seven participating centres of the Central Pancreas
Consortium were used in this Institutional Review Board-
approved retrospective review. The data from each centre were
collected using a specified menu-driven database and then com-
bined for analysis. Patients were included for analysis if they
underwent pancreatic resection for pancreatic ductal adenocarci-
noma between 1 January 2000 and 1 January 2009. Patients who
had a grossly positive (R2) resection margin (n = 9) and those
receiving neoadjuvant chemotherapy were excluded from the
queried database.
Definitions
Diabetes was defined by both patient history and biochemical
means, as previously described by Chu et al.10 Patients with a past
medical history of DM as well as those with a pre-operative fasting
glucose greater than 125 mg/dl or two or more outpatient random
glucose levels above 199 mg/dl were considered to be diabetic.
Body mass index (BMI) was calculated and reported as kg/m2. All
pathological data, including greatest tumour diameter and lymph
node status were collected as reported by each individual institu-
tion’s clinical pathologists. The resection margins were defined as
R0 (microscopically negative) and R1 (microscopically positive).
Circumferential margins including the transection, superior
mesenteric artery and retroperitoneum were examined. The R1
margin was specifically defined as less than 1 mm. The same defi-
nition for positive margins was used at all centres. Patients with an
R2 margin (grossly positive) were excluded from this analysis.
Pathological analysis was performed at the centre where a resec-
tion occurred, without a central review. Adjuvant chemotherapy
and radiotherapy data were collected. As the purpose of this ret-
rospective review was not to look at the impact of a specific
regimen, the data were reported as categorical variables (yes/no).
Disease-free survival was defined as the time interval between
diagnosis of pancreatic cancer and recurrence of disease, with
patients alive without disease censored at the last follow-up.
Follow-up was similar at all centres, and included office visits,
computed tomography imaging and CA 19-9 levels every 3 to 4
months. Recurrence was defined based on imaging and rising CA
19-9 levels. Overall survival was defined as the time interval
between diagnosis and death, with censoring at the last follow-up.
Post-operative deaths were defined as any death that occurred
within 90 days post-operatively, regardless of admission status.
Likewise, post-operative complications were counted regardless of
the patient’s admission status.
Statistical analyses
The cohort of interest (n = 509) was then randomly divided into
a training set (n = 245) and a test set (n = 264). Kaplan–Meier
analyses were performed on the training set in order to identify
metabolic and clinicopathological factors associated with both
disease-free survival (DFS) and overall survival (OS). Patients
who were alive and recurrence free at the time of their last
follow-up visit were censored in the analyses for DFS (right cen-
sored). Using forced entry of those covariates that attained signifi-
cance in the univariate analyses (P < 0.050), multivariable Cox’s
proportional-hazards models were developed to determine factors
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that were independently associated with survival. Two simple
integer-based scoring systems that could be used to model OS and
DFS were then created based on the beta-coefficients of our mul-
tivariable analyses. The scores were then tested for their associa-
tion with survival in the test set using log-rank tests. An
asymptotically unbiased concordance index, which differs from
the Harrell’s c-statistic in that it is robust to the degree of censor-
ing, was used to determine the overall discriminatory ability of
our OS scoring system, as well as that of the currently proposed
AJCC system (7th edition) for patients diagnosed with resectable
disease (stages I to IIB).47 It should be noted that the patient
cohort used to derive and test the OS and DFS scores included the
209 patients from Chu’s prior study concerning the significance of
diabetes to survival,10 and these patients would have been divided
between the training and validation sets via the process of random
sampling described above.
Results
Clinicopathological data
In all, 509 patients from seven academic medical centres under-
went a resection for PDAC from 1 January 2000 to 1 January 1
2009. The median age of the entire cohort was 67.0 years [inter-
quartile range (IQR) = 58.0–74.0], with a median follow-up time
of 14.5 months. At the end of the study 334 patients were
deceased. There were 159 (31.2%) patients who had diabetes as a
pre-operatively identified comorbidity, of which 68 (43%) were
insulin dependent. The median BMI was 26 kg/m2 (IQR =
23–29 kg/m2). The clinicopathological features of patients in both
the training and test sets are indicated in Table 1.
Operative and pathological data
For the entire cohort studied, the majority of patients were treated
with a pancreaticoduodenectomy (n = 442, 86.8%), of whom 53
(10.4%) required vascular resection to achieve tumour extirpa-
tion. The remaining individuals underwent distal (n = 57, 11.2%),
central (n = 1, 0.2%) or a subtotal pancreatectomy (n = 7, 1.4%).
The median operative blood loss was 500 ml (range 50–5650 ml)
and 41.8% (n = 213) of patients received a blood component
transfusion peri-operatively. The post-operative complication
rate was 56.6% (n = 288), with a 90-day mortality of 5.5%
(n = 28). The most common type of complication was infectious,
representing 44.2% (127 patients) of all complications. Eight per
cent (n = 41) of patients developed a pancreatic fistula.
While most patients had an R0 resection, 127 (25.0%) tumour
specimens had microscopically positive margins. The median
tumour size was 3.1 cm (IQR = 2.5–4.0 cm), and nodal metastases
were present in 57% (n = 290) of patients. Of the patients with
tumour-positive lymph nodes, the median lymph node (LN) ratio
Table 1 Clinicopathological characteristics of training (n = 245) and test set (n = 264) populations
Factor Training set n = 245 Test set n = 264 P-value
n (%) n (%)
Age 65 137 (55.9) 149 (56.4) 0.929
Male 115 (46.9) 134 (50.8) 0.425
Pre-operative DM 78 (31.8) 81 (30.7) 0.848
BMI  30 55 (22.4) 53 (20.1) 0.517
1 other comorbidity (cardiac, renal and pulmonary) 61 (24.9) 82 (31.1) 0.139
Type of resection 0.091
Whipple 199 (81.2) 190 (72.0)
Whipple with portal or superior mesenteric vein resection 21 (8.6) 32 (12.1)
Distal pancreatectomy 20 (8.2) 37 (14.0)
Central pancreatectomy 0 (0) 1 (0.4)
Subtotal pancreatectomy 4 (1.6) 3 (1.1)
Adjuvant chemotherapy 144 (58.8) 141 (53.4) 0.272
Adjuvant radiotherapy 82 (33.5) 64 (24.2) 0.073
Peri-operative complication 136 (55.5) 152 (57.6) 0.655
Histological grade 0.934
Well-differentiated 28 (11.4) 30 (11.4)
Moderately-differentiated 141 (57.6) 158 (59.8)
Poorly differentiated/anaplastic 72 (29.4) 75 (28.4)
R1 margin 61 (24.9) 66 (25.0) 0.979
Nodal ratio >0.1 110 (44.9) 130 (49.2) 0.373
Tumour size 2 cm 213 (86.9) 229 (86.7) 0.895
DM, diabetes mellitus; BMI, body mass index.
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was 0.25 (IQR = 0.1–0.44) and the median number of positive
LNwas 2 (IQR= 1–4).Themedian number of nodes harvestedwas
10 (IQR = 6–16). The degree of tumour differentiation was as
follows: 11% (n= 58)well differentiated,59% (n= 299)moderately
differentiated and 29% (n = 147) poorly differentiated. Twenty-
eight per cent of patients (n = 146) received adjuvant chemo-
radiotherapy, whereas an additional 27% (n = 139) received
adjuvant chemotherapy only. The breakdown of the above factors
in the test set and training set are presented in Table 1.
Scoring systems
Univariate analysis of OS and DFS revealed pre-operative DM, a
tumour size 2 cm, lymph node ratio (LNR) > 0.1 and positive
resection margin were all associated with a poorer DFS and OS
(Table 2).Pre-operativeDM,LNR>0.1, tumour size2 cmandan
R1 resection all retained significance in themultivariate analysis of
OS (Table 3). Each of these factors, with the exception of tumour
size2 cm,was also independently associated with DFS (Table 3).
The median OS and DFS in the training set was 18.3 (IQR
11.2–30.0) months, and 13.2 (IQR 8.0–26.8) months, respectively.
Scoring systems to model OS and DFS were then created based
on the beta coefficients from these multivariable analyses. For the
OS score, tumour size2 cm and R1 resection were each assigned
one point, whereas two points were assigned for each of pre-
operative DM or LNR > 0.1, respectively. A similar integer-based
scoring system was designed for DFS (R1 margin = 1 point, tumor
size2 cm = 2 points, pre-operative DM or LNR > 0.1 = 4 points
each).
The OS score was significantly associated with survival in the
training set (Table 4) When applied to the test set, the OS score
was similarly associated with survival, and adequate discrimina-
tion was observed between each of the point groups (P < 0.001 for
all pair-wise comparisons). A comparable stratification of median
survival time by point-group was also observed for the DFS score
in both the training and test sets, although with poorer discrimi-
nation between point groups 3–5 and 6–8 (P < 0.050 for all
pair-wise comparisons).
A comparison between the current AJCC staging system (7th
edition) and the proposed OS score is presented in Fig. 1. While
the AJCC system adequately discriminated between stages IIB vs.
Table 2 Univariate analyses of factors associated with OS and DFS in the training set (n = 245)
Factor Median OS P-value Median DFS P-value
Months (95% CI) (Months)
Pre-operative DM 14.8 (14.2–15.4) <0.001 10.2 (9.0–11.4) <0.001
Tumour size  2 cm 17.0 (15.1–18.9) 0.010 12.4 (10.8–14.0) 0.018
R1 margin 14.6 (12.2–17.0) <0.001 8.8 (7.4–10.2) <0.001
Nodal ratio > 0.1 15.8 (14.3–17.3) <0.001 11.0 (9.8–12.2) <0.001
BMI  30 kg/m2 15.8 (13.7–17.9) 0.143 10.5 (9.5–11.5) 0.164
OS, overall survival; DFS, disease-free survival; CI, confidence interval; SD, standard deviation; DM, diabetes mellitus; BMI, body mass index.
Table 3 Cox multivariate analysis of factors associated with OS and DFS in the training set
Factor OS DFS
HR 95% CI P-value HR 95% CI P-value
Pre-operative DM 1.99 1.40–2.82 <0.001 1.67 1.32–2.11 <0.001
Nodal ratio > 0.1 1.96 1.41–2.72 <0.001 1.84 1.47–2.31 <0.001
Tumour size  2 cm 1.80 1.06–3.02 0.030 1.32 0.95–1.84 0.093
R1 margin 1.62 1.13–2.32 0.008 1.28 1.01–1.64 0.044
OS, overall survival; DFS, disease-free survival; DM, diabetes mellitus; HR, hazard ratio; CI, confidence interval.
Table 4 Median survival times for OS and DFS scores in training (n = 245) and test (n = 264) sets
OS score DFS score
Points Training set Test set Points Training set Test set
Median OS months
(95% CI)
Median OS months
(95% CI)
Median DFS months
(95% CI)
Median DFS months
(95% CI)
0–1 34.3 (29.5–40.9) 31.0 (26.9–35.1) 0–2 26.0 (16.3–35.7) 15.8 (12.9–20.2)
2–3 17.4 (17.2–22.8) 17.5 (15.7–19.1) 3–5 12.6 (10.7–14.5) 10.8 (8.9–12.7)
4–6 14.6 (11.6–16.3) 14.2 (13.5–15.6) 6–8 8.8 (6.3–11.3) 8.6 (6.2–11.0)
OS, overall survival; DFS, disease-free survival; DM, diabetes mellitus; CI, confidence interval.
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IA, IB and IIA, respectively (P < 0.001 for all pairwise compari-
sons), poor discrimination was observed between all other stages.
Overall, the AJCC system exhibited moderate discriminatory
ability with a concordance index of 0.58  0.02. The OS score,
conversely, demonstrated adequate interstage discrimination
between all point groups (P < 0.001 for all interstage compari-
sons), and superior performance overall, with a concordance
index of 0.64 0.02. The components of the OS score responsible
for increased concordance over the AJCC system were diabetes
status and margin. The concordance for the OS score without
diabetes and margin status decreased by 0.06, essentially reducing
the discriminatory ability to that of the AJCC system. Similar
results were found for the comparison of the DFS score and the
AJCC stage (Fig 2).
Discussion
In spite of few encouraging reports in recent literature,2–4 the
prognosis for patients diagnosed with PDAC continues to be poor
and a minority of patients present with resectable disease. For
those patients that have undergone resection, prognosis is dictated
by tumour biology, clinicopathological characteristics, surgical
and peri-operative factors, and molecular genetics. Several of
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these variables have been shown to be associated with recurrence
and survival.5–9 The AJCC staging system48 is the most widely used
tool for estimating prognosis. More recently, the Memorial Sloan
Kettering group has developed and validated a prognostic nomo-
gram,49 which integrates additional prognostic factors in an
attempt to better model disease-specific survival for individual
patients. This system incorporates 18 different variables, and the
authors report a concordance index of 0.64. Although not all
variables were available to allow direct comparison of the
proposed nomogram to the MSKCC nomogram, the identical
reported concordance index suggests that the two systems are
similar in their predictive ability. The currently proposed scoring
system has the advantage of increased ease of use as a result of
lesser variables included.
On multivariable analysis, pre-operative DM, tumour size
2 cm, LNR > 0.1 and a positive resection margin were all iden-
tified to be independently associated with OS, whereas DM, LNR
> 0.1 and a positive resection margin were independently associ-
ated with DFS. These prognostic factors were then used to create
novel scoring systems that could predict survival outcomes. Pre-
operative DM was found to be an independent prognostic factor
for both DFS and OS in the current analysis. This is consistent
with recent literature examining the relationship between DM and
PDAC. Sperti et al.,12 in a retrospective study of 113 patients who
underwent surgical resection of PDAC found DM to be an inde-
pendently associated with long-term survival on multivariable
analysis. Chu et al.10 showed that DM was also associated with
increased tumour size and that new-onset DM patients (<24
months) exhibited this relationship most strongly. One-third of
the current patient population was found to be diabetic, which is
similar to that reported by others.28,50,51 Reasons for the poorer
survival seen with diabetes may be related to increased circulating
levels of insulin in these patients, as malignant tumours often over
express receptors for insulin and insulin-like growth factor 1.52,53
Thus, the higher insulin levels seen in diabetic patients may serve
as a trophic factor for malignancy. The other factors found to be
significant in the present study (lymph node involvement, tumour
size and resction margin), are already well described in the
literature.9,30–33,36–39,42–46,54–57
Additional investigators may continue with our proposed
scoring models but allow for other variables. For example, those
who had received neoadjuvant chemotherapy were excluded from
our cohort. Lim et al.,54 while recognizing the prognostic value of
biological characteristics, suggests that the most powerful deter-
minant of post-operative survival for the post-resection patient is
adjuvant chemoradiation therapy. Others have found adjuvant
therapies to be significant, as well.9,54,55 Contrarily, Schnelldorfer
et al.39 and others56,57 have not found adjuvant chemoradiation
therapy to have a significant influence on long-term survival.
There was not a significant effect for adjuvant chemo/
radiotherapy in the present study. However, this study was not
designed to properly evaluate the effects of adjuvant therapy, so
this conclusion should be interrupted with caution.
In terms of application of how this system may be applied,
consider a hypothetical patient with a 3-cm tumour that was
excised to microscopically negative (R0) margins. The patient had
pre-operative diabetes, and there was no metastatic or nodal
disease. Under the AJCC system this patient would be placed in
category IB, with a median OS of roughly 30 months based on
Kaplan–Meier curves obtained by applying the AJCC system to
the data set under analysis. Using the currently proposed OS
scoring system, the patient would have three points, with an
expected median OS of only 17 months, which is closer to that of
stage IIB patients. Thus application of the proposed scoring
system, with its increased discriminatory ability, more correctly
places the patient in a survival category that is one stage higher.
Such information is valuable not only for patient counselling and
follow-up planning, but for future research use as well in stratify-
ing patients by survival risk.
There have already been a number of schemes devised for pre-
dicting survival or PDAC as outlined above. The novel value of the
present study, therefore, is not necessarily that the proposed
scoring system is dramatically better then what is already avail-
able, but rather, that this represents the largest study to clearly
define the substantial negative impact that diabetes has on sur-
vival. Upon multivariable analysis, the hazard ratio for OS asso-
ciated with diabetes was higher than that for margin status,
metastatic lymph node ratio, or tumor size. For DFS, the hazard
ratio associated with diabetes was higher than those for tumor size
or margin status, although less important than metastatic nodal
ratio. Thus, not only is diabetes a significant predictor of survival,
but the present study is the first to demonstrate that it may have a
more important impact than more traditional risk factors. The
reasons for this survival impact are subjects for future study.
Pancreatic adenocarcinoma continues to be a difficult disease to
diagnose and treat. In spite advances in surgical techniques and
peri-operative care, consistent long-term survival remains elusive.
Significant improvements in long-term survival will probably
come from the development of effective systemic therapies and
that this should be the goal of future research. It is the authors’
hope that the development of scoring systems such as the one
offered herein prove useful for clinicians and researchers who deal
with pancreatic adenocarcinoma. Limitations of the present study
include its retrospective design and a lack of central pathological
review. The present study was confined to specialized centres and
thus may not be representative of the population of patients with
a pancreatic ductal adenocarcinoma as a whole.
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